Table 1.
Clinical details of patients with sarcoidosis.
| Total⁎ | Male | Female | ||
|---|---|---|---|---|
| Patients | 146 | (100.0%) | 56 (38.4%) | 90 (61.6%) |
| Age (years, mean ± SD) | 46 | ± 12.7 | 40 ± 11.8 | 50 ± 11.9 |
| Age of onset (years, mean ± SD) | 45 | ± 12.5 | 39 ± 12.1 | 48 ± 11.4 |
| Disease stage | ||||
| 0 | 10 | (6.8%) | 2 (1.4%) | 8 (5.5%) |
| I | 64 | (43.8%) | 22 (15.1%) | 42 (28.8%) |
| II | 52 | (35.6%) | 22 (15.1%) | 30 (20.5%) |
| III | 15 | (10.3%) | 5 (3.4%) | 10 (6.8%) |
| IV | 5 | (3.4%) | 5 (3.4%) | 0 (0.0%) |
| Smoking | ||||
| Yes | 102 | (69.9%) | 27 (18.5%) | 75 (51.4%) |
| No | 31 | (21.2%) | 21 (14.4%) | 10 (6.8%) |
| Ex | 13 | (8.9%) | 8 (5.5%) | 5 (3.4%) |
| Diagnostic tests | ||||
| Biopsy (of non-caseating epitheloid cell granulomas in tissue/organ affected) | 135 | (92.5%) | 45 (30.8%) | 90 (61.6%) |
| Lymph nodes | 32 | (21.9%) | 10 (6.8%) | 22 (15.1%) |
| Skin | 27 | (18.5%) | 5 (3.4%) | 22 (15.1%) |
| Lung | 13 | (8.9%) | 4 (2.7%) | 9 (6.2%) |
| Endrobrochial | 31 | (21.2%) | 12 (8.2%) | 19 (13.0%) |
| Transbronchial | 32 | (21.9%) | 14 (9.6%) | 18 (12.3%) |
| Clinical-radiological | 54 | (37.0%) | 27 (18.5%) | 27 (18.5%) |
| Hypercalciuria | 35 | (24.0%) | 19 (13.0%) | 16 (11.0%) |
| Heart involvment | 9 | (6.2%) | 3 (2.1%) | 6 (4.1%) |
| Eye involvment | 9 | (6.2%) | 2 (1.4%) | 7 (4.8%) |
| Skin | 32 | (21.9%) | 6 (4.1%) | 26 (17.8%) |
| Löfgren | 27 | (18.5%) | 11 (7.5%) | 16 (11.0%) |
| Nervous system | 2 | (1.4%) | 0 (0.0%) | 2 (1.4%) |
| Patients with relapses | 36 | (24.7%) | 14 (9.6%) | 22 (15.1%) |
| Follow-up available > 2 years (average 5 years) | 121 | (82.9%) | 43 (29.5%) | 78 (53.4%) |
| FVC% | 99 | ± 20 | 93 ± 23 | 102 ± 17 |
| FEV1% | 94 | ± 21 | 90 ± 23 | 96 ± 20 |
| DLCO% | 83 | ± 24 | 85 ± 23 | 82 ± 25 |
⁎
The percentages are based on total number of samples.